Literature DB >> 161336

Circumstantial evidence for increased potassium conductance of membrane of cardiac muscle by 2-nicotinamidoethyl nitrate (SG-75).

T Yanagisawa, K Satoh, N Taira.   

Abstract

The mechanism of action of 2-nicotinamidoethyl nitrate (SG-75), was investigated by the use of arterially blood-perfused papillary muscle preparations of the dog. All drugs were administered intra-arterially. SG-75 shortened the effective refractory period (ERP) and decreased the rate of automaticity and developed tension of the papillary muscle, whereas verapamil failed to change the ERP despite a decrease in the developed tension. SG-75 in extremely high doses induced ventricular fibrillation. Methacholine produced decreases in the rate of automaticity and developed tension, and the actions were abolished by atropine. The SG-75-induced decreases in two parameters were not modified by atropine. These results indicate that the cardiac action of SG-75 differs from that of calcium-antagonistic vasodilators and it is suggested that the basic mechanism of action of SG-75 involves an increase in potassium conductance in the membrane of cardiac muscle, without mediation through muscarinic receptors.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 161336     DOI: 10.1254/jjp.29.687

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  15 in total

Review 1.  Electrophysiologic effects of potassium channel openers.

Authors:  W Haverkamp; M Borggrefe; G Breithardt
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

Review 2.  Pharmacology of the potassium channel openers.

Authors:  G Edwards; A H Weston
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

3.  Effect of 2-nicotinamidethyl nitrate (SG-75) on the membrane potential of left atrial muscle fibres of the dog. Increase in potassium conductance.

Authors:  T Yanagisawa; N Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

4.  Nicorandil and cardiovascular performance in anaesthetized pigs with a concentric coronary artery stenosis.

Authors:  L M Sassen; L K Soei; T J Heere; L J van Woerkens; P R Saxena; P D Verdouw
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

5.  Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.

Authors:  F Yoneyama; K Satoh; N Taira
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 6.  Pharmacology and therapeutic effects of nicorandil.

Authors:  M Kinoshita; K Sakai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

7.  Prevention of postischemic reperfusion injury: the improvement of myocardial tissue blood flow after ischemia by terminal nicorandil-Mg cardioplegia.

Authors:  H Orita; M Fukasawa; S Hirooka; T Minowa; H Uchino; M Washio
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

8.  Effects of chronic treatment with a low dose of nicorandil on the function of the rat aorta during ageing.

Authors:  Stéphanie Raveaud; Paulette Mezin; Nicole Lavanchy; Barry Starcher; Robert P Mecham; Jean Verdetti; Gilles Faury
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-03-26       Impact factor: 2.557

9.  Electrophysiologic effects of nicorandil, a new antianginal agent, on action potentials and membrane currents of rabbit atrioventricular node.

Authors:  Y Habuchi; M Nishimura; Y Watanabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-05       Impact factor: 3.000

10.  The negative inotropic effect of nicorandil is independent of cyclic GMP changes: a comparison with pinacidil and cromakalim in canine atrial muscle.

Authors:  T Yanagisawa; H Hashimoto; N Taira
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.